Syros Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Syros Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-552.9%
Buyback Yield
| Total Shareholder Yield | -552.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
Jul 02Syros Pharmaceuticals: Rising Despite Dilution, A Must Look
Jan 14Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders
Sep 20Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609
Sep 13Syros Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if SYRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SYRS's dividend payments have been increasing.
Dividend Yield vs Market
| Syros Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (SYRS) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (SYRS) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate SYRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SYRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate SYRS's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SYRS has not reported any payouts.